Turn Therapeutics 10-Q: $13.1M Nine-Month Loss, Going Concern, $10.4M Cash Into Q3 2027
TTRX has more than doubled off its 52-week low of $2.57.
Summary
Turn Therapeutics' Q3 10-Q shows a $6.2 million quarterly loss driven mostly by a $3.34 million non-cash derivative remeasurement, $10.4 million of cash funding operations into Q3 2027, and a going-concern warning as it lines up a $2.7 million GEM draw-down and an undrawn $8.0 million loan tranche.
Key Events · Earnings and Guidance · TTRX
-
Q3 Loss Widens on Non-Cash Charge
Net loss was $6.2 million, or $(0.21) per share, versus $1.9 million, or $(0.07), a year earlier. The swing is largely a $3.34 million non-cash loss from change in fair value of a derivative liability instrument — no cash outflow and no new shares issued.
-
Cash Runway Into Q3 2027
Cash and cash equivalents were $10.4 million at September 30, 2026, against a $35.4 million accumulated deficit. Management expects funding to cover the Phase 2b AD trial and planned Phase 2a HS trial into Q3 2027.
-
Going Concern Warning Reiterated
The filing states capital resources may not fund operations for at least the next 12 months, raising substantial doubt about the ability to continue as a going concern. The company estimates it needs up to $60 to $65 million for Phase 3 AD and onychomycosis trials plus about $2.5 million for the Phase 2a HS study.
-
GEM Draw-Down and Undrawn Loan Tranche
On October 29, 2026 the company noticed a draw-down of 272,642 shares to GEM at a $10.00 threshold price, with $2.7 million advanced and the period expected to close November 20, 2026. The Avenue Capital facility's $8.0 million Tranche 2 was undrawn at September 30, 2026, pending Phase 3 dosing, a $10 million equity raise and positive Phase 2 AD data.
Analysis · TTRX · Life Sciences
The headline Q3 loss of $6.2 million versus $1.9 million a year earlier looks alarming, but $3.34 million of that red ink is a non-cash mark-to-market loss on a derivative liability — the warrant and conversion features were remeasured upward as the share price rose, so it reflects neither cash outflow nor new dilution. Operating expenses were essentially flat at $1.98 million, leaving the underlying burn stable. The real constraint is the balance sheet: $10.4 million of cash against a $35.4 million accumulated deficit, with management flagging substantial doubt about continuing as a going concern and estimating it needs $60 to $65 million for Phase 3 AD and onychomycosis trials plus $2.5 million for the HS study. Funding hinges on the GEM equity line — a $2.7 million draw-down noticed October 29, 2026, expected to close November 20, 2026 — and the Avenue Capital loan, where the $8.0 million Tranche 2 remains undrawn pending Phase 3 dosing, a $10 million equity raise and positive Phase 2 AD data. Phase 2b AD topline results are expected in the first quarter of 2027.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TTRX was trading at $9.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $289.5M. The 52-week trading range was $2.57 to $16.45. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.